

Portola Pharmaceuticals (USA): Constituent Deletion Changes in FTSE RAFI™ Index Series

02 July 2020

Following the completion of the tender offer of Portola Pharmaceuticals (USA, constituent) by Alexion Pharmaceuticals, please see details of affected indexes and effective dates below:

Index	Effective From Start of Trading
FTSE RAFI US 1500 Mid Small Index - QSR	08 July 2020

In the absence of an active market, Portola Pharmaceuticals will be removed from the index at the merger terms of \$18.00 USD.

For further information please contact FTSE Russell Client Services at info@ftserussell.com or call:

Australia +1800 653 680 Hong Kong +852 2164 3333 Japan +81 3 4563 6346 London +44 (0) 20 7866 1810 New York +1866 551 0617

Alternatively please visit our website at www.ftserussell.com

Terms of Use | Copyright © 2020 FTSE Russell